What Happened?
, -based Seaport Therapeutics Appointed Antony Loebel as CMO and President Clinical Development
About the Company
Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. We have a proven strategy of advancing clinically validated mechanisms previously held back by limitations we overcome with our proprietary Glyph technology platform. All the therapeutic candidates in our pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce hepatotoxicity and other side effects. We are led by an experienced team that was involved in inventing and developing KarXT and other neuropsychiatric medicines, and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders. For more information, please visit www.seaporttx.com or connect with us on X (formerly Twitter) @SeaportTx
About the Person
Antony Loebel is CMO and President Clinical Development at Seaport Therapeutics. Previously, Antony held various senior HR leadership roles in the industry.
Info Source
News
Short Profile